Stefaan Van Gool is senior clinical investigator at the Fund for Scientific Research Flanders (FWO-V). Wim Maes is supported by the Olivia Hendrickx Research Fund. Hilko Ardon and Tina Verschuere are research fellows supported by the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT). Sofie Van Cauter is research fellow in the Department of Radiology. Steven De Vleeschouwer is supported by the Klinisch Onderzoeksfonds UZ Leuven.
Dendritic Cell Therapy of High-Grade Gliomas
Article first published online: 4 SEP 2009
© 2009 The Authors. Journal Compilation © 2009 International Society of Neuropathology
Volume 19, Issue 4, pages 694–712, October 2009
How to Cite
Van Gool, S., Maes, W., Ardon, H., Verschuere, T., Van Cauter, S. and De Vleeschouwer, S. (2009), Dendritic Cell Therapy of High-Grade Gliomas. Brain Pathology, 19: 694–712. doi: 10.1111/j.1750-3639.2009.00316.x
- Issue published online: 4 SEP 2009
- Article first published online: 4 SEP 2009
- Received 15 June 2009; accepted 17 June 2009.
- clinical trials;
- dendritic cells;
- high-grade glioma;
- translational medicine
The prognosis of patients with malignant glioma is poor in spite of multimodal treatment approaches consisting of neurosurgery, radiochemotherapy and maintenance chemotherapy. Among innovative treatment strategies like targeted therapy, antiangiogenesis and gene therapy approaches, immunotherapy emerges as a meaningful and feasible treatment approach for inducing long-term survival in at least a subpopulation of these patients. Setting up immunotherapy for an inherent immunosuppressive tumor located in an immune-privileged environment requires integration of a lot of scientific input and knowledge of both tumor immunology and neuro-oncology. The field of immunotherapy is moving into the direction of active specific immunotherapy using autologous dendritic cells (DCs) as vehicle for immunization. In the translational research program of the authors, the whole cascade from bench to bed to bench of active specific immunotherapy for malignant glioma is covered, including proof of principle experiments to demonstrate immunogenicity of patient-derived mature DCs loaded with autologous tumor lysate, preclinical in vivo experiments in a murine orthotopic glioma model, early phase I/II clinical trials for relapsing patients, a phase II trial for patients with newly diagnosed glioblastoma (GBM) for whom immunotherapy is integrated in the current multimodal treatment, and laboratory analyses of patient samples. The strategies and results of this program are discussed in the light of the internationally available scientific literature in this fast-moving field of basic science and translational clinical research.